Meeting Coverage:

American Academy of Ophthalmology

AAO: 2023

Drug-Eluting IOLs

Show Description +

Kenneth J. Mandell, MD, PhD, highlights the potential benefits of incorporating drug-eluting IOLs into future practice, including the OcuRing-K (LayerBio), a single, nonsteroidal, sustained-release implant.

Posted: 11/03/2023

Keywords:

OcuRing-K

LayerBio

Up Next

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA


A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Diversity in Ocular Oncology

Basil K. Williams Jr, MD

Update on Glaucoma Lasers

Aaki Shukla, MD, and Mary Qiu, MD

Genetics: Now or Later

Inas Aboobakar, MD

Drug-Eluting IOLs

Kenneth Mandell, MD, PhD

Drug-Eluting IOLs

Kenneth J. Mandell, MD, PhD, highlights the potential benefits of incorporating drug-eluting IOLs into future practice, including the OcuRing-K (LayerBio), a single, nonsteroidal, sustained-release implant.

Posted: 11/03/2023

Keywords:

OcuRing-K

LayerBio

Please log in to leave a comment.

Comments

Stephen Orr

1 year ago

I have wondered about this concept for many many years. Makes a LOT of sense to me. Drug-eluting stents (DES) have been in clinical use in Cardiology for over a decade! Why is surgical Ophthalmology so far behind Cardiology?

More From AAO: 2023 Coverage